Merck & Company (MRK) Gets a Buy from Jefferies
Jefferies analyst maintained a Buy rating on Merck & Company today and set a price target of $138.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In addition to Jefferies, Merck & Company also received a Buy from Barclays’s Emily Field in a report issued yesterday. However, on the same day, TD Cowen maintained a Hold rating on Merck & Company (NYSE: MRK).
Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $16.4 billion and a net profit of $2.96 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $3.74 billion
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Last month, Chirfi Guindo, the CMO of MRK sold 10,000.00 shares for a total of $1,214,500.00.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
- Terns Pharmaceuticals downgraded to Hold from Buy at Truist
- Merck announces results from CORALreef AddOn study of enlicitide decanoate
- Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
